International Journal Of Bilogical Sciences
.: Home > International Journal Of Bilogical Sciences > 2016 > Volume 12 Number 6 > Hao Zhang1*, Zhen-long Ye1*, Zhen-gang Yuan1, Zheng-qiang Luo2, Hua-jun Jin1, Qi-jun qian1, 2, 3
New Strategies for the Treatment of Solid Tumors with CAR-T Cells
Hao Zhang1*, Zhen-long Ye1*, Zhen-gang Yuan1, Zheng-qiang Luo2, Hua-jun Jin1, Qi-jun qian1, 2, 3
1. Laboratory of Viral and Gene Therapy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China; 2. Xinyuan Institute of Medicine and Biotechnology College of Life Science, Zhejiang Sci-Tech University, Hangzhou 310018, China; 3. Ningbo NO.5 Hospital (Ningbo Cancer Hospital), Ningbo 315201, China. *These authors contributed equally to this manuscript. Corresponding authors: Qi-Jun Qian, Tel: + 86-21-81875371; Fax: + 86-21-65580677; E-mail: firstname.lastname@example.org; Hua-Jun Jin, Tel: + 86-21-81875372; E-mail: email@example.com.
Recent years, we have witnessed significant progresses in both basic and clinical studies regarding novel therapeutic strategies with genetically engineered T cells. Modification with chimeric antigen receptors (CARs) endows T cells with tumor specific cytotoxicity and thus induce anti-tumor immunity against malignancies. However, targeting solid tumors is more challenging than targeting B-cell malignancies with CAR-T cells because of the histopathological structure features, specific antigens shortage and strong immunosuppressive environment of solid tumors. Meanwhile, the on-target/off-tumor toxicity caused by relative expression of target on normal tissues is another issue that should be reckoned. Optimization of the design of CAR vectors, exploration of new targets, addition of safe switches and combination with other treatments bring new vitality to the CAR-T cell based immunotherapy against solid tumors. In this review, we focus on the major obstacles limiting the application of CAR-T cell therapy toward solid tumors and summarize the measures to refine this new cancer therapeutic modality.
chimeric antigen receptor, adoptive immunotherapy, cell therapy, solid tumor
Date Deposited : 04 Nov 2016 22:19
Official URL: http://www.ijbs.com/v12i6
Last Modified : 04 Nov 2016 22:19
Volume 12, Number 6, April 2016
Full Text Original